For professional investors in Brazil

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE0002141913

NAV
USD 55.48
As of 18 Aug 2022

1-Day Change
USD -0.19 (-0.34%)
As of 18 Aug 2022

Morningstar Rating


Morningstar ratings are based on the representative share class of this fund and are dated to the last month-end upon availability from Morningstar.

Overview

Quarterly update

Watch the investment team recap this quarter.

Note: Filmed in July 2022

 

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.
Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

More

The Fund invests at least 80% in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country.
The Fund may also invest in other assets including cash and money market instruments.
The investment manager may use derivatives (complex financial instruments) to reduce risk, to manage the Fund more efficiently, or to generate additional capital or income for the Fund.
The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Less

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care
Past performance does not predict future returns. 
 

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Performance

Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Cumulative & Annualised Performance (%)
As of 31 Jul 2022
I2 USD (Net) MSCI World Health Care NR
  
  Cumulative Annualised
1MO YTD 1YR 3YR 5YR 10YR Since Inception
31 Mar 2000
I2 USD (Net) 3.63 -10.27 -8.44 9.56 9.42 14.38 7.85
MSCI World Health Care NR 3.26 -7.39 -2.69 12.66 10.44 12.41 7.76
 
  Annualised
3YR 5YR 10YR Since Inception
31 Mar 2000
I2 USD (Gross) - 11.20 16.29 9.67
MSCI World Health Care NR + 2.00% - 12.64 14.66 9.92
Calendar Year Returns (%)
As of 31 Dec 2021
I2 USD (Net) MSCI World Health Care NR
YTD 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
I2 USD (Net) -13.41 5.60 24.37 28.04 2.76 21.48 -13.17 6.55 33.68 53.88 23.73
MSCI World Health Care NR -10.32 19.80 13.52 23.24 2.51 19.80 -6.81 6.60 18.10 36.27 17.54
 
YTD 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
I2 USD (Gross) -12.73 7.26 26.34 30.16 4.48 23.54 -11.70 8.35 36.00 56.57 25.90
MSCI World Health Care NR + 2.00% -9.44 22.20 15.79 25.71 4.57 22.19 -4.95 8.73 20.46 38.99 19.90
Calendar Year Returns (%)
Year I2 USD (Net) Index
2021 5.60 19.80
2020 24.37 13.52
2019 28.04 23.24
2018 2.76 2.51
2017 21.48 19.80
2016 -13.17 -6.81
2015 6.55 6.60
2014 33.68 18.10
2013 53.88 36.27
2012 23.73 17.54
2011 7.03 9.46
2010 7.16 2.41
2009 25.68 18.89
2008 -30.45 -21.50
2007 20.78 3.94
2006 -2.90 10.47
2005 10.80 9.00
2004 13.33 6.00
2003 26.73 19.50
2002 -30.67 -17.98
2001 -20.02 -13.24
2000 from 2000-03-31 17.40 25.65
FEE INFORMATION
Initial Charge 2.00%
Annual Charge 1.50%
Ongoing Charge
(As of 31 Dec 2021)
1.56%

Portfolio

Top Holdings (As of 31 Jul 2022)
% OF FUND
UnitedHealth Group Inc 6.70
AstraZeneca PLC 4.62
AbbVie Inc 3.77
Eli Lilly & Co 2.92
Thermo Fisher Scientific Inc 2.79
Merck & Co Inc 2.59
Bristol-Myers Squibb Co 2.53
Roche Holding AG 2.51
Abbott Laboratories 2.44
Danaher Corp 2.43
Total 33.30
Sector Allocation % OF FUND % OF FUND (As of 31 Jul 2022)
Regional Allocation % OF FUND % OF FUND (As of July 31, 2022)

Documents

  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives towards the aim of achieving its investment objective. This can result in 'leverage', which can magnify an investment outcome and gains or losses to the Fund may be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share/unit class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a hedged share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency, the hedging strategy itself may create a positive or negative impact to the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • Some or all of the ongoing charges may be taken from capital, which may erode capital or reduce potential for capital growth.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
  • Information on compliance with EU sustainable related disclosures can be found here.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Henderson Management SA may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KIID before making any final investment decisions.